Phenotype Landscape Modeling for Personalized Drug Selection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for genetic disease diagnosis, pharmaceutical treatment, and drug discovery fail to account for the unique complex genetic and environmental backgrounds of individuals, leading to incomplete characterization of phenotypic results and diverse therapeutic responses.

Innovation Solution

A method utilizing spatial covariance relationships to generate predicted clinical phenotype landscapes, enabling personalized drug treatment strategies by analyzing genotype variants and cellular phenotypes, and administering treatments based on genotype characteristics.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If traditional genetic disease diagnosis and treatment methods are used, then general disease characterization is achieved, but personalized phenotypic prediction and therapeutic optimization cannot be realized

Engineering Contradiction:

Improvephenotypic prediction accuracyVSAvoidspatial covariance analysis system

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent performs preliminary actions by pre-computing spatial covariance relationships between genotype variants and cellular phenotypes to generate predicted clinical phenotype landscapes before clinical trials. This allows patient stratification and treatment selection to be based on pre-established predictive models, improving phenotypic prediction accuracy without adding complexity to the actual clinical intervention process

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent introduces predicted clinical phenotype landscapes as an intermediary between genotype data and treatment outcomes. These landscapes serve as a computational mediator that translates complex genotype information into actionable phenotypic predictions, enabling personalized treatment selection without requiring direct complex interactions between all genetic variants and treatment responses

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If comprehensive genotype analysis is performed for all patients, then personalized treatment optimization is achieved, but clinical trial complexity and resource requirements increase

Engineering Contradiction:

Improvepersonalized treatment strategyVSAvoidclinical trial design

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent segments patients into distinct subgroups based on their genotype characteristics and predicted phenotypic landscapes. This segmentation allows for tailored treatment strategies for each subgroup while simplifying overall clinical trial design by reducing the heterogeneity within treatment groups. Patients are divided into cohorts based on spatial covariance patterns, enabling focused analysis and treatment optimization for each segment

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the parameter of treatment selection from generic disease-based criteria to genotype-specific predicted phenotypic parameters. By using spatial covariance relationships to predict clinical phenotypes, the system transforms treatment assignment from a one-size-fits-all approach to a parameter-driven personalized approach, where treatment selection is based on predicted response characteristics rather than uniform disease classification

Inventive Principle:

Principle #35Parameter changes

3Reliability

If existing variant characterization methods are used, then known genotype-phenotype relationships are identified, but incomplete information leads to diverse and unpredictable therapeutic responses

Engineering Contradiction:

Improvetherapeutic response predictionVSAvoidphenotypic characterization completeness

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent implements feedback by using observed clinical trial responses to refine and validate the predicted phenotypic landscapes. The system continuously compares predicted phenotypes with actual treatment outcomes, using this feedback to improve the accuracy of spatial covariance relationships and enhance future phenotypic predictions. This closed-loop approach increases reliability of therapeutic response prediction while systematically reducing information loss through iterative model improvement

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS12584173B2Methods for disease treatment and drug discovery

Publication Date: 2026.03.24 THE SCRIPPS RES INST

AI summary

Drug administration is performed in view of variation spatial profiling (VSP) of patients or potential patients. Spatial-covariance (SCV) relationships relate the position of the disease-associated variant in the polypeptide chain with cell-based models and clinical features of disease. An understanding of SCV relationships for a sparse collection of known fiduciary variants can be used to generate the shape of phenotype landscapes that measure the differential disease behavior for unknown variants, and between distinct cell and tissue environments in patients. The phenotype landscapes can determine which pharmaceutical compounds are administered to potential patients.